Chromium

Summary

Chromium (CHEMBL1201228) is a phase-3 clinical-stage small molecule; indicated across 1 condition including polycystic ovary syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201228
Name	Chromium
Type	Small molecule
Max phase	3

Also known as: Biochrome, Chromic cation, Chromic ion, Chromium, Chromium(iii) cation, Chromium(iii) ion, elemental, metallic, Dinakrome, CHROMIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
polycystic ovary syndrome	3	MONDO:0008487	EFO:0000660

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
Not specified	8
PHASE2	3
PHASE3	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06709313	PHASE4	ACTIVE_NOT_RECRUITING	Effect of Chromium on Blood Sugar After Sacroiliac Joint Injection
NCT06405243	PHASE3	NOT_YET_RECRUITING	Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients
NCT01368328	PHASE3	UNKNOWN	Effect of the Chromium Nicotinate on Type 2 Diabetes
NCT00067626	PHASE2	COMPLETED	Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes
NCT00152893	PHASE2	COMPLETED	To Determine if Chromium Nicotinate Supplementation Will Improve Insulin Resistance in HIV Patients With Metabolic Abnormalities
NCT00759993	PHASE2	TERMINATED	Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units.
NCT00846248	Not specified	COMPLETED	Chromium and Insulin Resistance
NCT01107431	Not specified	COMPLETED	Effects of a Dietary Supplement Containing L-Arabinose and Trivalent Patented Food-source of Chromium on Blood Glucose and Insulin
NCT01709123	Not specified	COMPLETED	Effects of Micronutrient (Chromium) Supplementation on Diabetes
NCT03038282	Not specified	UNKNOWN	Effects of Chromium on Insulin Resistance in Alzheimer Disease Patients
NCT03503201	Not specified	COMPLETED	Effect of Chromium Supplementation on Intracytoplasmatic Sperm Injection (ICSI) Outcomes in Polycystic Ovary Syndrome Ladies
NCT03552315	Not specified	COMPLETED	Effects of a Carbonated Water Enriched With Amino Acids and Chromium Picolinate (Good Idea®) on Glucose Homeostasis.
NCT05573607	Not specified	COMPLETED	Effects of a Dietary Supplement on Markers of Glucose Control and Quality of Life
NCT05686915	Not specified	UNKNOWN	MARS MRI in Revision THA With a Ceramic Femoral Head and Titanium Sleeve

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).